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A previous phase II trial demonstrated that the fully human anti-IL-12/23 mAb briakinumab was efficacious in
moderate-to-severe psoriasis. A subsequent 52-week, double-blind, placebo-controlled phase III study
evaluated induction and maintenance treatment. Patients were randomized 2:1 to briakinumab (200mg at
weeks 0 and 4 and 100mg at week 8) or placebo; those with physician’s global assessment ‘‘clear’’ or ‘‘minimal’’
(PGA ‘‘clear/minimal’’) at week 12 were then re-randomized 2:2:1 to briakinumab 100 mg every 4 weeks (q4-wk),
every 12 weeks (q12-wk), or to matching placebo to week 52. Primary analyses conducted by nonresponder
imputation compared proportions achieving PGA ‘‘clear/minimal’’ (weeks 12 and 52) andX75% improvement in
psoriasis area and severity index (PASI 75; week 12). In all, 76.0% of briakinumab vs. 4.3% of placebo-treated
patients achieved PGA ‘‘clear/minimal,’’ and 80.7% vs. 4.5%, respectively, achieved PASI 75 at week 12 (Po0.001
each). At week 52, 79.2% of q4-wk-treated patients achieved PGA ‘‘clear/minimal’’ compared with 41.6% and
6.0% of q12-wk and placebo-treated patients, respectively (Po0.001 for all treatment comparisons). Higher
numbers of the following adverse events (AEs) of interest were observed with briakinumab during the placebo-
controlled period, suggesting the need for surveillance for these events: serious infections (five vs. one event
with briakinumab vs. placebo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous cell
carcinomas (SCCs)), and major adverse cardiovascular events (MACEs; five vs. zero events).
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INTRODUCTION
Psoriasis is a complex, chronic inflammatory disease that not
only manifests in the skin but also appears to be operating at the
systemic level, and, particularly in its severe form, may increase
the risk for cardiovascular events such as acute myocardial
infarction (Gelfand et al., 2006; Nestle et al., 2009). Immune
pathways mediated by a variety of cytokines appear to have an
important role in psoriasis disease mechanisms, as evidenced by
the significant efficacy of antitumor necrosis factor (TNF)-a agents
(Reich et al., 2005; Menter et al., 2008; Saurat et al., 2008) and
the more recent success of IL-12 and IL-23 (IL-12/23) blockers
(Kimball et al., 2008; Papp et al., 2008). Psoriasis has traditionally
been believed to be mediated by T cells, with activation of
Th1 by IL-12 and the release of IFN-g having a prominent role
(Yawalkar et al., 1998; Nestle et al., 2009). In addition, a newly
characterized IL-17-releasing T cell, activated by IL-23, has been
implicated (Di Cesare et al., 2009).
IL-12 and IL-23 are heterodimeric proteins that share a
common p40 subunit, and IL-23 in particular has been found
to be highly expressed in psoriatic skin lesions (Yawalkar
et al., 1998; Lee et al., 2004). A previous phase II study
demonstrated that briakinumab, a fully human anti-IL12/23
mAb was efficacious for the treatment of moderate-to-severe
psoriasis (Kimball et al., 2008). This study further evaluated
the efficacy and safety of briakinumab and compared two
maintenance therapy dosing regimens against placebo. Safety
results from this trial raise concern that adverse events (AEs),
both expected and unexpected based on the mechanism of
action of the drug, should be further evaluated in a larger
psoriatic patient population.
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RESULTS
Induction phase
A total of 1,465 patients were randomized (briakinumab
n¼981; placebo n¼ 484; Figure 1). Baseline demographics
and clinical characteristics were comparable between treat-
ment groups (Table 1a). The post hoc analysis showed that
underlying cardiovascular risk factors were also generally
similar (Table 1b).
At week 12, physician’s global assessment of ‘‘clear’’ or
‘‘minimal’’ (PGA ‘‘clear/minimal’’) response was signifi-
cantly higher with briakinumab than with placebo (treatment
difference: 71.8% (95% confidence interval (CI): 66.3, 77.2);
Figure 2), as was the percentage with 75% improvement
in psoriasis area and severity index (PASI 75; treatment
difference: 76.2% (95% CI: 70.8, 81.6), Po0.001; both con-
firmed by sensitivity analyses). In all, 61.6% of briakinumab-
treated patients achieved PASI 90, and 32.2% achieved
PASI 100 (Table 2). Dermatology Life Quality Index
(DLQI) was also significantly improved with briakinumab:
37.1% vs. 1.9% of briakinumab- versus placebo-treated
patients, respectively, achieved DLQI of ‘‘0’’ at week 12
(Table 2).
Among subgroups of briakinumab-treated patients,
60–70% achieved PGA ‘‘clear/minimal’’ or PASI 75 response
at week 12, regardless of prior biological treatment, baseline
PASI score, history of psoriatic arthritis, or baseline weight
(Table 2). The response levels in each subgroup were superior
to those of placebo.
Maintenance phase
A total of 766 patients achieved PGA ‘‘clear/minimal’’ at
week 12 and entered the maintenance phase; 97.3% (n¼ 745)
were from the briakinumab group (Figure 1). A total of 596
patients were re-randomized to continue briakinumab, either
every 4 weeks (q4-wk; n¼ 298) or every 12 weeks (q12-wk;
n¼298), whereas 149 were allocated to placebo and thus
withdrawn from briakinumab (the withdrawal group). The
demographic and clinical characteristics at baseline were
generally similar among the three treatment groups and were
comparable to the induction phase groups (Table 1a).
1,865 Patients screened
1,465 Randomized
2:1
981 Allocated to
briakinumab
(200 mg at week 0 and 4,
100 mg at week 8236 Patients withdrew:
11 Adverse event
190 Lack of efficacy1
8 Protocol violation
6 Lost to follow-up
745 Re-randomized
2:2:1
298 Allocated to
briakinumab
(100 mg every 4 weeks)
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298 Allocated to
briakinumab
(100 mg every 12 weeks)
149 Allocated to placebo
(every 4 weeks)
4 Allocated to placebo
(every 4 weeks)
1 Patient withdrew: 2 Patients withdrew:
1 Protocol violation
1 Other
1 Lack of efficacy2
8 Allocated to briakinumab
(100 mg every 12 weeks)
9 Allocated to briakinumab
(100 mg every 4 weeks)
2 Patients withdrew:
2 Lack of efficacy2
7 Completed
9 Included in intention-
to-treat analysis
6 Completed
8 Included in intention-
to-treat analysis
3 Completed
23 Completed
126 Patients withdrew:
1 Adverse event
118 Lack of efficacy2
2 Lost to follow-up
3 Lost to follow-up
3 Protocol violation
125 Lack of efficacy2
7 Adverse event
145 Patients withdrew:44 Patients withdrew:
3 Adverse event
29 Lack of efficacy2
3 Protocol violation
6 Lost to follow-up
2 Other
1 Unknown
254 Completed 153 Completed
298 Included in intention-
to-treat analysis
298 Included in intention-
to-treat analysis
2 Other
6 Other 3 Unknown
1 Unknown
4 Included in intention-
to-treat analysis
149 Included in intention-
to-treat analysis
484 Allocated to placebo
(week 0, 4, and 8)
21 Re-randomized
2:2:1
463 Patients withdrew:
3 Adverse event
431 Lack of efficacy1
7 Protocol violation
5 Lost to follow-up
12 Other
5 Unknown
13 Other
8 Unknown
Figure 1. Study flow and patient disposition. 1Lack of efficacy was defined as physician’s global assessment (PGA) score of ‘‘mild’’ or higher. 2Lack of efficacy
was defined as a PGA score of ‘‘moderate’’ or higher.
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PGA ‘‘clear/minimal’’ response rates through week 52
were higher in the two briakinumab treatment groups
compared with placebo (treatment withdrawal) and were
greatest with q4-wk dosing (Figure 3a). In the withdrawal
group, 6% had PGA ‘‘clear/minimal’’ at week 52 compared
with 41.6% and 79.2% of q12-wk- and q4-wk-treated
patients, respectively (Po0.001, both comparisons).
Maintenance phase PASI 75 response rates were highest
with q4-wk dosing compared with q12-wk or placebo
(Figure 3b). In the q4-wk arm, PASI 100 responses generally
continued to increase through week 20 and were sustained
for the remainder of the maintenance phase (Figure 3c). In all,
63.4% of patients dosed q4-wks had a PASI 100 response at
week 52 compared with 23.5% and 4.0% in the q12-wk and
withdrawal groups, respectively (Po0.001).
Safety results
The most frequently reported AEs are shown in Table 3. While
back pain occurred in all treatment groups, and infrequently
during the induction phase, during the maintenance phase,
numerically more q4-wk-treated patients had back pain
compared with q12-wk- or placebo-treated patients (5.4%
vs. 2.0% and 2.0%, respectively).
Overall, 3.3% of briakinumab-treated patients experi-
enced serious AEs during the induction and/or maintenance
phases. Serious AE rates were similar between treatments
during induction; however, during the maintenance phase,
these were numerically higher with q12-wk dosing compared
with q4-wk or placebo (3.0% vs. 1.3% and 1.3%, respec-
tively).
The induction phase infection rate was numerically higher
with briakinumab (22.3% vs. 19.8% with placebo), and
higher with q4-wk dosing versus q12-wk and placebo during
the maintenance phase (44.4% vs. 35.9% and 27.5%,
respectively; Po0.05, q4-wk vs. placebo). Exposure-adjusted
rates of infection did not increase in the maintenance phase
compared with the induction phase: 113.1 events per 100
patient-years (E/100 PY) for briakinumab during the induction
phase (234.3 PY) compared with 102.5 E/100 PY and 81.2 E/
100 PY in the q4-wk (226.3 PY) and q12-wk (182.2 PY)
Table 1a. Demographic and clinical characteristics at baseline across treatment groups in induction and
maintenance phases and for the study population overall
Induction phase Maintenance phase1
Briakinumab
(N=981)
Placebo
(N=484)
Briakinumab
q4-wk (N=298)
Briakinumab
q12-wk (N=298)
Withdrawal from
briakinumab (placebo)
(N=149) Total2 (N=1,465)
Demographic characteristics
Age (years) 45.7 (13.2) 45.1 (13.5) 44.6 (13.3) 45.5 (12.6) 45.0 (13.4) 45.5 (13.3)
Sex, male 666 (67.9%) 343 (70.9%) 206 (69.1%) 201 (67.4%) 100 (67.1%) 1,009 (68.9%)
Weight (kg) 93.8 (23.6) 93.1 (23.0) 91.3 (21.3) 93.7 (23.4) 89.3 (24.6) 93.5 (23.4)
Race
Asian 44 (4.5%) 18 (3.7%) 13 (4.4%) 7 (2.3%) 14 (9.4%) 62 (4.2%)
Black 31 (3.2%) 15 (3.1%) 7 (2.3%) 7 (2.3%) 5 (3.4%) 46 (3.1%)
White 888 (90.5%) 432 (89.3%) 275 (92.3%) 278 (93.3%) 127 (85.2%) 1,320 (90.1%)
Other 18 (1.8%) 19 (3.9%) 3 (1.0%) 6 (2.0%) 3 (2.0%) 37 (2.5%)
Clinical characteristics
Body surface area affected (%) 24.8 (16.3) 25.7 (16.9) 23.7 (14.8) 22.3 (13.5) 25.2 (17.1) 25.1 (16.5)
Psoriasis area and severity index 19.1 (7.5) 19.3 (7.3) 18.4 (6.5) 18.3 (6.2) 18.9 (8.2) 19.2 (7.4)
Dermatology life quality index (DLQI)3 12.8 (7.0) 12.7 (6.9) 12.7 (7.1) 12.6 (6.8) 11.9 (7.0) 12.8 (7.0)
Duration of psoriasis (years)4 18.9 (12.3) 19.2 (11.9) 19.1 (12.1) 18.5 (12.1) 18.9 (12.4) 19.0 (12.2)
Patients with psoriatic arthritis 290 (29.6%) 150 (31.0%) 86 (28.9%) 79 (26.5%) 42 (28.2%) 440 (30.0%)
Physician’s global assessment
Moderate 514 (52.4%) 242 (50.0%) 170 (57.0%) 164 (55.0%) 85 (57.0%) 756 (51.6%)
Severe 408 (41.6%) 218 (45.0%) 113 (37.9%) 124 (41.6%) 53 (35.6%) 626 (42.7%)
Very severe 59 (6.0%) 24 (5.0%) 15 (5.0%) 10 (3.4%) 11 (7.4%) 83 (5.7%)
1Includes all patients randomized to briakinumab during the induction phase.
2Includes all patients with at least 1 dose of briakinumab at any point in the study.
3Baseline DLQI missing for several patients: briakinumab, N=980; placebo, N=481; withdrawal from briakinumab (placebo), N=148; total, N=1,461.
4Duration of psoriasis missing for several patients: briakinumab, N=977; placebo, N=482; briakinumab every 12 weeks (q12-wk), N=296; total, N=1,459.
Data are mean (SD) or n (%).
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groups, respectively, during the maintenance phase. For all
briakinumab exposure through week 52 (662.2 PY), the
infection rate was 100.1 E/100 PY.
A numerically higher rate of serious infection was observed
with briakinumab versus placebo during the induction phase
(0.5% vs. 0.2%, respectively). Cellulitis, observed in 0.4%
of briakinumab-treated patients, was the most frequently
reported serious infection. Beyond week 12, no serious
infections were observed with q4-wk dosing, and low rates
were observed with q12-wk and placebo (0.7% and 0.7%,
respectively). There were no cases of tuberculosis infection.
Combining the placebo-controlled and maintenance
treatment periods, nonmelanoma skin cancers (NMSCs)
occurred in 10 briakinumab-treated patients (6 squamous
cell carcinomas (SCCs) and 4 basal cell carcinomas; Table 3);
none were reported with placebo. Four SCCs were diagnosed
within the first 12 weeks of treatment. Two additional
noncutaneous malignancies of squamous cell origin were
reported (one nasopharyngeal, study day 15; one tonsil, study
day 266).
Major adverse cardiovascular events (MACEs), defined as
nonfatal myocardial infarction, nonfatal stroke, or cardio-
vascular death, occurred in seven briakinumab-treated
patients. During the induction phase, five MACEs occurred
with briakinumab, whereas none occurred with placebo
(0.5%, 95% CI 0.2, 1.2 vs. 0%, 95% CI 0.0, 0.8; onset ranged
from days 21 to 55). Two additional MACEs occurred in
briakinumab-treated patients during the maintenance phase
Table 1b. Risk factors for cardiovascular disease at baseline by induction-phase treatment group
Briakinumab
(N=981), n (%)
Placebo
(N=484), n (%)
Total
(N=1,465), n (%)
Cardiovascular disease medical history
Any cardiovascular disease1 395 (40.3) 178 (36.8) 573 (39.1)
Angina 6 (0.6) 2 (0.4) 8 (0.5)
Cardiac arrhythmia 8 (0.8) 5 (1.0) 13 (0.9)
Congestive heart failure 4 (0.4) 1 (0.2) 5 (0.3)
Coronary artery disease 16 (1.6) 5 (1.0) 21 (1.4)
Hypertension 302 (30.8) 139 (28.7) 441 (30.1)
Myocardial infarction 19 (1.9) 6 (1.2) 25 (1.7)
Peripheral vascular disease (arterial) 2 (0.2) 2 (0.4) 4 (0.3)
Peripheral vascular disease (venous) 2 (0.2) 2 (0.4) 4 (0.3)
Syncope 2 (0.2) 0 2 (0.1)
Valvular heart disease 2 (0.2) 2 (0.4) 4 (0.3)
Other 165 (16.8) 74 (15.3) 239 (16.3)
Cardiovascular and metabolic syndrome risk factors2
Hypertension (blood pressure X140/90mmHg, or taking antihypertensive drug) 426 (43.4) 199 (41.1) 625 (42.7)
Cigarette smoking 304 (31.0) 148 (30.6) 452 (30.9)
Diabetes mellitus 98 (10.0) 40 (8.3) 138 (9.4)
Obesity (BMI X30 kgm–2) 508 (51.8) 245 (50.6) 753 (51.4)
Male X45 years 374 (38.1) 175 (36.2) 549 (37.5)
Female X55 years 78 (8.0) 40 (8.3) 118 (8.1)
LDL cholesterol 4100mgdl–1 542 (58.1) 253 (55.0) 795 (57.1)
Triglycerides 4200mgdl–1 289 (29.6) 132 (27.4) 421 (28.9)
HDL cholesterol o40mgdl–1 294 (30.1) 145 (30.1) 439 (30.1)
Multiple cardiovascular risk factors
X1 Risk factor 928 (94.6) 456 (94.2) 1,384 (94.5)
X2 Risk factors 804 (82.0) 386 (79.8) 1,190 (81.2)
X3 Risk factors 600 (61.2) 268 (55.4) 868 (59.2)
X4 Risk factors 361 (36.8) 166 (34.3) 527 (36.0)
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
1Not equal to sum of subcategories, as patients could be counted in multiple subcategories if they had multiple conditions.
2Percentages are based on all patients with baseline data.
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(on days 131 and 225), resulting in an exposure-adjusted
MACE rate of 1.06 E/100PY, 95% CI 0.43, 2.18. One of
the five induction phase events was a cardiac arrest on day 38
resulting in death (the patient was a 50-year-old man, with
several underlying cardiovascular risk factors: body mass
index X30 kgm–2, baseline triglyceride level 4200mgdl–1,
and blood glucose X126mgdl–1). All other events also
occurred in patients with X3 preexisting cardiovascular risk
factors.
DISCUSSION
This large, randomized, placebo-controlled trial in patients
with moderate-to-severe psoriasis demonstrated solid efficacy
responses to a treatment modality targeting the IL-12/23
pathways, further validating previous work that has linked
these cytokines to the psoriasis disease process. Following 12
weeks of treatment, the primary end points of PGA ‘‘clear/
minimal’’ and PASI 75 were achieved by 76% and 81%
of briakinumab-treated patients, respectively. Maintenance
phase PASI 100 response rates continued to rise through
week 20; almost half of the patients initially randomized
to briakinumab and re-randomized to q4-wk dosing achiev-
ed and maintained a PASI 100 response through 52 weeks.
For each end point, response was maintained best with
q4-wk dosing.
The high degree of clinical response in various patient
subgroups is also notable. In the Phoenix II trial, Papp et al.
(2008) identified several baseline characteristics more com-
mon among patients achieving only a partial response to
ustekinumab: higher baseline bodyweight, more severe
disease, presence of psoriatic arthritis, and prior systemic or
biological treatment failure. Patients with prior biological
treatment failure are generally more difficult to treat.
However, most patients in our study with such a history
achieved a PGA ‘‘clear/minimal’’ and PASI 75 response,
highlighting the considerable efficacy benefits observed with
briakinumab. It is noteworthy that the PASI 75 response rate
we observed in this subgroup compares to that seen overall in
phase III trials of the anti-TNF-a antibodies infliximab and
adalimumab (Menter et al., 2008; Saurat et al., 2008;
Centocor Ortho Biotech Remicade [package insert], 2009)
and is higher than that reported for the TNF-neutralizing
fusion protein etanercept (Immunex, Enbrel [package insert],
2010). Similarly, high response levels were seen in patients
having severe disease or arthritic involvement, and in those
with higher weight, further underscoring the robust effects of
this anti-IL-12/23 agent.
On the basis of briakinumab’s mechanism of action, key
safety findings from this study were either expected or
unexpected. For example, animal studies have provided
ample evidence that the IL-12/IFN-g axis is a critical pathway
in providing protection from infection and has an important
role in tumor immunity. IL-12/IL-23p40-deficient mice are
highly susceptible to numerous pathogens including viruses,
intracellular bacteria, parasites, and fungi (Langrish et al.,
2004). Humans with mutations in the IL-12/23 signaling
pathway show a more restricted susceptibility to infection,
mostly limited to infection by Bacille Calmette-Gue´rin and
Mycobacteria and by various non-typhi species of Salmonella
(Filipe-Santos et al., 2006). Nevertheless, IL-12- and IL-23-
deficiency states in humans and mouse knockout models
suggest a potential increased susceptibility to infection. Thus,
not unexpectedly, we observed higher rates of infection
with briakinumab versus placebo. Infection rates in this phase
III study were generally consistent with preliminary findings
in an earlier, dose-ranging study (Kimball et al., 2008).
It is noteworthy that our results suggest that the risk for
infection does not increase over time, as the exposure-
adjusted rate of infections did not increase from the induction
to the maintenance phase.
Rates of serious infection were low, with the most
commonly observed event being cellulitis. It is noteworthy
that no tuberculosis or serious opportunistic fungal infection
occurred in this large study; only a single, nonserious case of
candidiasis occurred with q4-wk maintenance treatment. It is
important to note, however, that a potential increased risk for
infection with an immunomodulating treatment is not
unexpected, and monitoring for these events during anti-IL-
12/23 treatment is warranted.
The protective role of IL-12/IL-23 in tumor immunity has
been studied in several animal models. IL-12 or IL-12/IL-23-
deficient mice exposed to UV irradiation have a greater risk
of UV-induced NMSC, possibly because of reduced DNA
repair in the absence of IL-12 (Schwarz et al., 2002; Maeda
et al., 2006). Mice treated with antibodies to IL-12/IL-23
showed enhanced tumor formation when challenged with
squamous carcinoma cells (Langowski et al., 2006). Despite
limitations in translating cell- and animal-based research to
the bedside, some reduced tumor immunity in humans may
be expected as with any immunomodulatory agent. Skin
cancers are not uncommon in a psoriasis population (e.g.,
unmasking of preexisting lesions with effective treatment, or
extensive psoralen plus UVA exposure). In this study, we
observed several NMSCs in briakinumab-treated patients,
whereas none were observed with placebo. Four events
were SCCs occurring within the first 12 weeks of treatment.
100 PGA “clear” or “minimal,” placebo (N = 484)
PGA “clear” or “minimal,” briakinumab (N = 981)
PASI 75, placebo (N = 484)
PASI 75, briakinumab (N = 981)80
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***
***
***
***
%
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Figure 2. Proportions achieving physician’s global assessment (PGA) ‘‘clear’’
or ‘‘minimal’’ or psoriasis area and severity index (PASI) 75 by treatment
group during the induction phase. Intention-to-treat analysis: patients with
missing scores were considered nonresponders. ***Po0.001 briakinumab
versus placebo.
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In addition, the typical balance toward a higher incidence of
basal cell carcinoma was not observed; rather, the rate of
SCC was higher. It is noteworthy that two of the noncuta-
neous, solid tumors were SCCs. No NMSCs were observed in
placebo-treated patients. Thus, the events observed with
briakinumab warrant attention and highlight the need to
closely monitor these events with wider use of anti-IL-12/23
agents.
Unexpected and of significance in this trial, seven MACEs
occurred, all in patients receiving briakinumab (five during
the placebo-controlled period, two during the maintenance
phase); this was unprecedented in the phase II trial (Kimball
et al., 2008). Recent evidence suggests that patients with
psoriasis are more likely to have cardiovascular risk factors
(Gisondi et al., 2007; Ludwig et al., 2007) and higher risk for
myocardial infarction (Gelfand et al., 2006). Compelling
evidence from a large, prospective, population-based study in
a broadly representative cohort of patients with psoriasis,
identified from the UK’s General Practice Research Database
(Gelfand et al., 2006), found that younger age and severe
disease independently raised the relative risk of myocardial
infarction by three times. Cytokines within atherosclerotic
lesions have been reported to promote a Th1 response
leading to production of IFN-g, as well as a cascade of other
cytokines (including TNF, IL-1, and IL-6), creating an
inflammatory milieu that promotes atherosclerosis (Hansson,
2005). Considering the role of Th1-related cytokines in
psoriasis, current evidence suggests an association between
the inflammatory processes involved in psoriasis and those
inherent in coronary artery disease. However, data are
lacking to distinguish whether other variables potentially
associated with psoriasis, such as poor management of
lifestyle risk factors or stress, may be contributing to the risk
of heart disease.
Recent conflicting evidence from murine models suggests
that IL-17 may have a complex role in atherosclerosis
Table 2. Overall results on the PASI and DLQI, and clinical response across subgroups of patients at week 12 by
intention-to-treat analysis, using nonresponder imputation
Briakinumab (N=981) Placebo (N=484) P-value
PGA ‘‘clear’’ or ‘‘minimal’’ 746 (76.0) 21 (4.3) o0.001
PASI 75 792 (80.7) 22 (4.5) o0.001
PASI 90 604 (61.6) 7 (1.4) o0.001
PASI 100 316 (32.2) 0/484 o0.001
DLQI of ‘‘0’’ 364 (37.1) 9 (1.9) o0.001
PGA ‘‘clear’’ or ‘‘minimal’’ PASI 75
Briakinumab Placebo Briakinumab Placebo
Prior treatment1
Biologics 114/173 (65.9) 1/76 (1.3) 129/173 (74.6) 1/76 (1.3)
Lack of response to anti-TNF2 84/137 (61.3) 0/72 96/137 (70.1) 0/72
No biologics 632/808 (78.2) 20/408 (4.9) 663/808 (82.1) 21/408 (5.1)
Disease severity1
Baseline PASI 420 207/299 (69.2) 4/166 (2.4) 237/299 (79.3) 7/166 (4.2)
Baseline PASI p20 539/682 (79.0) 17/318 (5.3) 555/682 (81.4) 15/318 (4.7)
History of psoriatic arthritis1
Yes 208/290 (71.7) 1/150 (0.7) 228/290 (78.6) 2/150 (1.3)
No 538/691 (77.9) 20/334 (6.0) 564/691 (81.6) 20/334 (6.0)
Weight1
X100 kg 233/346 (67.3) 4/172 (2.3) 252/346 (72.8) 4/172 (2.3)
o100 kg 513/635 (80.8) 17/312 (5.4) 540/635 (85.0) 18/312 (5.8)
Abbreviations: anti-TNF, tumor-necrosis factor antagonist; DLQI, dermatology life quality index (scores range from 0 to 30, with lower scores reflecting
better health-related quality of life); PASI, psoriasis area and severity index.
1Po0.001 for briakinumab versus placebo.
2Other reasons for discontinuation are not included as the number of patients was too small.
Values are n (%).
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(Hansson and Hermansson, 2011). Although the methods
used in these studies are diverse, some results suggest that
IL-17 may promote atherogenesis (Pejnovic et al., 2009),
whereas others suggest stabilization of plaques and reduced
atherosclerotic lesion development (Taleb et al., 2009). At
this time, however, research in this area is limited, and the
role of IL-17 in atherosclerosis is far from clear.
In contrast to seven MACEs observed with briakinumab in
this study, five of which occurred during the placebo-
controlled period, no MACEs occurred with placebo.
Complicating the interpretation of this finding, no MACEs
were observed in any other clinical trial of briakinumab in
psoriasis (Kimball et al., 2008; Gottlieb et al., 2011; Reich
et al., 2011; Strober et al., 2011). This compares with
inconsistent MACE findings reported for the IL-12/23 blocker,
ustekinumab, in moderate-to-severe psoriasis, where MACE
occurred in three of four reported clinical trials (Krueger
et al., 2007; Leonardi et al., 2008; Griffiths et al., 2010).
Conversely, no MACEs were observed with ustekinumab in
the Phoenix II trial (Papp et al., 2008). Our post hoc analysis
of underlying cardiac risk factors revealed a slight imbalance
between groups; however, these marginal differences may
not account for the disproportion in observed cardiac events.
Because MACEs observed in this study and those observed in
ustekinumab trials have been mostly isolated to anti-IL-12/23
treatment-exposed patients, more evidence will be crucial to
determine whether this new therapeutic approach, the
potential risk posed by psoriasis itself, or a combination of
the two is contributing to their occurrence. In light of the
weight of evidence thus far, identification of cardiac risk
factors before commencing anti-IL-12/23 treatment in
patients with psoriasis, and close monitoring during therapy,
will be important precautionary measures.
Ultimately, the decision to use a therapeutic agent is based
on the needs of the patient and judgment of the clinician.
There remain significant needs for patients with severe
psoriasis who have failed or cannot be treated with existing
modalities. In this paper, we have demonstrated that
briakinumab could offer considerable relief from psoriasis
for these groups. Critically, however, the decision is compli-
cated by the suggestions of AEs that could be associated with
therapy. It is not necessarily surprising that therapy for
psoriasis and immune-mediated disease, directed against
the immune system, may have higher rates of infections and
skin cancers when substantially high rates of response are
identified. However, this trial also identifies unexpected
events, particularly MACE, for which no causal relationship is
established. These events, as well as potentially other AEs
with rare occurrence, suggest that continued vigilance be
used in evaluating the safety profile of anti-IL-12/23 agents.
Comparisons with information from other databases of
patients treated for moderate-to-severe psoriasis is underway,
to delineate comparative risks over a longer duration of
therapy. In the meantime, the trends identified in this study
provide critical information for clinicians and patients alike
when making decisions on the treatment of severe psoriasis.
MATERIALS AND METHODS
Study protocol, assignment, masking, participant flow,
and follow-up
A 52-week, randomized, double-blind, placebo-controlled trial was
conducted in two phases: a 12-week induction phase, followed by a
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Figure 3. Maintenance-phase efficacy results. Maintenance of (a)
physician’s global assessment (PGA) ‘‘clear’’ or ‘‘minimal’’ and proportions
achieving (b) psoriasis area and severity index (PASI) 75 and (c) PASI 100
through week 52. 1One patient in the briakinumab every-4-week group was
re-randomized but did not receive any study drug in the maintenance
phase. 2Represents all patients who received briakinumab in the induction
phase, had a PGA score of ‘‘clear’’ or ‘‘minimal’’ at week 12, and were
re-randomized in the maintenance phase. Intention-to-treat analysis: patients
with missing scores were considered nonresponders. *Po0.05, **Po0.01,
and ***Po0.001 briakinumab every 4 weeks and every 12 weeks versus
placebo; for briakinumab every 4 weeks versus every 12 weeks, Po0.001 for
all endpoints from weeks 20 to 52, and Po0.01 for PASI 75 at week 16.
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Table 3. AEs observed across treatment groups during the induction phase and maintenance phase, and for all
patients exposed to briakinumab from baseline to week 52
Induction phase Maintenance phase1
Briakinumab
(N=981)
Placebo
(N=484)
Briakinumab
q4-wk (N=297)
Briakinumab
q12-wk (N=298)
Placebo
(N=149)
All briakinumab
(N=998)
Any AE 517 (52.7%) 229 (47.3%) 215 (72.4%)2 183 (61.4%) 86 (57.7%) 688 (68.9%)
Most frequently observed 3
Nasopharyngitis 63 (6.4%) 20 (4.1%) 39 (13.1%)2 35 (11.7%) 9 (6.0%) 117 (11.7%)
Headache 53 (5.4%)2 9 (1.9%) 14 (4.7%) 10 (3.4%) 4 (2.7%) 67 (6.7%)
Upper respiratory tract infection 49 (5.0%) 20 (4.1%) 48 (16.2%)2 24 (8.1%) 8 (5.4%) 113 (11.3%)
Back pain 15 (1.5%) 9 (1.9%) 16 (5.4%) 6 (2.0%) 3 (2.0%) 36 (3.6%)
Any AE leading to discontinuation of
study drug
17 (1.7%) 4 (0.8%) 3 (1.0%) 6 (2.0%) 1 (0.7%) 27 (2.7%)
Any serious AE 20 (2.0%) 6 (1.2%) 4 (1.3%) 9 (3.0%) 2 (1.3%) 33 (3.3%)
Deaths 1 (0.1%)4 0 0 05 0 1 (0.1%)
AEs of special interest
Any infection 219 (22.3%) 96 (19.8%) 132 (44.4%)2 107 (35.9%) 41 (27.5%) 397 (39.8%)
Any serious infection 5 (0.5%) 1 (0.2%) 0 2 (0.7%) 1 (0.7%) 8 (0.8%)
Appendicitis 1 (0.1%) 0 0 0 0 1 (0.1%)
Cellulitis 1 (0.1%) 0 0 2 (0.7%) 1 (0.7%) 4 (0.4%)
Cytomegalovirus infection 0 1 (0.2%) 0 0 0 0
Pneumonia 2 (0.2%) 0 0 0 0 2 (0.2%)
Pyelonephritis 1 (0.1%) 0 0 0 0 1 (0.1%)
Sepsis 0 0 0 1 (0.3%) 0 1 (0.1%)
Any opportunistic infection 0 2 (0.4%) 1 (0.3%) 0 0 1 (0.1%)
Candidiasis 0 1 (0.2%) 1 (0.3%) 0 0 1 (0.1%)
Cytomegalovirus 0 1 (0.2%) 0 0 0 0
Any malignancy 6 (0.6%) 0 3 (1.0%) 5 (1.7%) 0 14 (1.4%)
Squamous cell carcinoma 4 (0.4%)6 0 0 2 (0.7%)6 0 6 (0.6%)
Basal cell carcinoma 0 0 2 (0.7%) 2 (0.7%) 0 4 (0.4%)
Other 2 (0.2%)7 0 1 (0.3%)8 1 (0.3%)9 0 4 (0.4%)
Any major adverse cardiovascular event 5 (0.5%) 0 1 (0.3%) 1 (0.3%) 0 7 (0.7%)10
Cardiac arrest 1 (0.1%) 0 0 0 0 1 (0.1%)
Myocardial infarction 3 (0.3%) 0 0 1 (0.3%) 0 4 (0.4%)
Stroke 1 (0.1%) 0 0 0 0 1 (0.1%)
Acute coronary syndrome 0 0 1 (0.3%) 0 0 1 (0.1%)
Abbreviations: AE, adverse event; q4-wk, every 4 weeks; q12-wk, every 12 weeks.
1Briakinumab-treated patients from induction phase.
2Po0.05, briakinumab versus placebo.
3AEs with X5% incidence in any group.
4One fatal cardiac arrest (also listed in AEs of special interest, cardiovascular).
5One death 445 days after study discontinuation (listed in AEs of special interest, cardiovascular).
6Four patients discontinued due to squamous cell carcinoma (SCC), three during induction and one during maintenance phase.
7One patient diagnosed with lung cancer on study day 43, and 1 with nasopharyngeal cancer on study day 15; both patients discontinued.
8One patient diagnosed with colon cancer on study day 285; patient discontinued.
9One patient diagnosed with tonsil cancer on study day 266; patient discontinued.
10All major adverse cardiovascular events (MACEs), excluding one event of acute coronary syndrome, resulted in discontinuation.
Data are n (%); patients may have had X1 AEs.
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40-week maintenance phase (ClinicalTrials.gov: NCT00570986)
(see Appendix for the list of study investigators). At baseline, patients
were randomized 2:1 to receive subcutaneous briakinumab (200mg,
weeks 0 and 4; 100mg, week 8) or matched placebo. At week 12,
patients achieving a PGA ‘‘clear/minimal’’ were re-randomized 2:2:1
to receive one of three regimens during the maintenance phase:
briakinumab 100 mg at a q4-wk or q12-wk interval, or placebo at a
q4-wk interval (treatment withdrawal). Randomization was adminis-
tered via an interactive voice response system, thus concealing
treatment allocation from all study personnel and subjects. To
maintain the blind, patients in the q12-wk group received matched
placebo injections at 4-week intervals between briakinumab doses.
The study was conducted from December 2007 through June
2009 at 116 clinical sites within the United States and Canada.
Adults aged X18 years were eligible to participate if they had
moderate-to-severe plaque-type psoriasis (defined asX10% affected
body surface area, PGA ofX‘‘moderate,’’ and PASI ofX12) forX6
months and were candidates for systemic therapy or phototherapy.
Women of childbearing potential were to use at least two methods of
contraception throughout participation and for 60 days following the
last dose; pregnant or breast-feeding women were excluded, as were
patients with any of the following: prior anti-IL-12 exposure; active
skin conditions interfering with psoriasis evaluation; poorly con-
trolled medical condition; hepatic, renal, or hematologic disease;
malignancy history, other than successfully treated basal cell
carcinoma or nonmetastatic SCC, or cervical carcinoma in situ;
and infections or risk for severe infections. Tuberculosis screening
was conducted before enrollment; those with a purified protein
derivative test result of X5mm induration (regardless of prior BCG
vaccination) and/or chest X-ray suggestive of latent tuberculosis
were not enrolled, unless prophylactic treatment as recommended
by local guidelines was instituted before initiating study treatment.
The following therapies, not permitted during the study, had to be
discontinued within the respective timeframes before baseline:
topical treatments (including corticosteroids (except low potency
topical corticosteroids on the palms, soles, face, inframammary area,
or groin), vitamin D analogs, or retinoids) and UVB phototherapy,
2 weeks; psoralen plus UVA phototherapy and systemic nonbio-
logical therapies, 4 weeks; or biological therapies, 12 weeks. Oral or
injectable corticosteroids were not permitted.
Study objectives and outcomes
The efficacy and safety of briakinumab in moderate-to-severe
psoriasis were evaluated, and two maintenance dosing regimens
were compared against placebo. Four primary analyses were
conducted: (1a) PGA ‘‘clear/minimal’’ and (1b) PASI 75 response
rates for briakinumab versus placebo at week-12; and at week-52,
(2a) PGA ‘‘clear/minimal’’ for q4-wk versus placebo and (2b) PGA
‘‘clear/minimal’’ for q12-wk versus placebo. These analyses were
conducted in a step-down manner to control type I error.
Secondary analyses compared PASI 75, PASI 90, and PASI 100
response rates over time, and proportions achieving a DLQI of ‘‘0.’’
PASI 100, PASI 90, and DLQI of ‘‘0’’ were ranked secondary end
points analyzed in a step-down manner. Outcomes were compared
between briakinumab arms and between each dose group versus
placebo.
Subgroup analyses of PGA ‘‘clear/minimal’’ and PASI 75
responses were conducted in patients with/without prior biological
treatment (including prior ‘‘lack of response’’ to anti-TNFs); with/
without psoriatic arthritis; baseline PASI 420/p20; and baseline
weight X100 kg/o100 kg. The prevalence of cardiovascular med-
ical history/risk factors (Executive Summary of the Third NCEP, Adult
Treatment Panel III, 2001) was determined post hoc by treatment
group.
AEs were collected throughout the study andp45 days following
the last dose, to account for the estimated half-life of briakinumab.
An independent external Cardiovascular Endpoints Committee
comprised of two cardiologists and one neurologist used prespeci-
fied definitions to adjudicate MACE. Each case was identified in a
blinded manner; all serious AE line listings were reviewed, with a
detailed review of all deaths and selected serious AEs representing
potential cardiovascular outcomes.
Statistical analyses
A sample size of 1,350 patients (randomized 2:1, briakinumab:
placebo) was estimated to provide490% power to demonstrate the
superiority of briakinumab over placebo (assuming that 70% vs. 4%
of briakinumab- vs. placebo-treated patients would achieve PGA
‘‘clear/minimal’’ at week 12). Assuming that 630 briakinumab-
treated patients would be re-randomized 2:2:1 (q4-wk: q12-wk:
placebo) at week 12, this sample size would provide 490% power
to detect an 18% treatment difference, assuming 40% of patients
re-randomized to placebo could maintain PGA ‘‘clear/minimal’’ at
week 52.
Re-randomization at week 12 was stratified by treatment
assigned at week 0. All statistical tests were two-tailed with a-level
of 0.05. Efficacy analyses were conducted in the intention-to-treat
population, and all outcomes presented were analyzed using
nonresponder imputation. Primary end points were analyzed using
the Cochran–Mantel–Haenszel test adjusted by center; secondary
variables were analyzed using w2 test. The normal approximation
to the binomial distribution was used to set up the two-sided 95% CI
for the difference in response rates. Sensitivity analyses were
performed using last observation carried forward. Primary end
points and ranked secondary end points were analyzed in a
hierarchical manner (i.e., successive comparisons were made
only if statistical significance was achieved with the previous
ranked variable). The proportion of patients experiencing AEs
was analyzed by Fisher’s exact test. Exposure-adjusted incidence
rates were calculated by dividing the number of observed events by
total patient-years of drug exposure and were expressed per 100
patient-years.
Patients initially randomized to placebo and re-randomized at
week 12 (n¼ 21) were excluded from the maintenance phase
efficacy analyses, as maintenance of response could not be assessed
in this group. All patients with at least one dose of briakinumab were
included in the safety analyses. One subject re-randomized to
briakinumab q4-wk did not receive treatment beyond week 12 and
was thus not included in the maintenance phase safety analysis.
Ethics
The study protocol and patient informed consent complied with the
Declaration of Helsinki Principles and were approved by an
independent ethics committee at each participating study site; no
study-related procedures were initiated before obtaining informed
consent.
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